B-cell targeted treatments for lupus: The journey counts as much as the destination
Authors:
- Géraldine FalgaroneGFGéraldine Falgarone
- Robin DhoteRDRobin Dhote
- Marie-Christophe BoissierMBMarie-Christophe Boissier
- 1 October 2012
- journal article
- review article
- Published by Elsevier in Joint Bone Spine
- Vol. 79 (5) , 437-440
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Anti-CRP antibodies in systemic lupus erythematosusJoint Bone Spine, 2010
- Targeting B cells with biologics in systemic lupus erythematosusExpert Opinion on Biological Therapy, 2010
- Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?Joint Bone Spine, 2010
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-upLupus, 2008
- Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of responseAnnals of the Rheumatic Diseases, 2008
- B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of responseAnnals of the Rheumatic Diseases, 2007
- Repeated B cell depletion in treatment of refractory systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2006
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosusArthritis & Rheumatism, 2003